Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

granulocytic sarcoma in a patient in MMR

More
9 years 11 months ago #794 by 966076155
34 female diagnosed CML May 2011, intermediate Sokal risk. Started on imatinib 400mg/d, obtained CCR at 3 months and MMR at 9 months.
In February 2013 bone fracture that was operated 3 times(!), the last in September 2013 when a local granulocytic sarcoma was found. At this time she was still in MMR and therefore a mutation analysis was not performed. She was treated with local radiotherapy (30Gy) and treatment was switched to Dasatinib 140mg/d.
At present she remains in MMR with good treatment tolerance. She has a compatible sibling, should we proceed to transplant?
  • Michele Baccarani
  • Michele Baccarani's Avatar
9 years 11 months ago #795 by Michele Baccarani
Replied by Michele Baccarani on topic Re: granulocytic sarcoma in a patient in MMR
This is a very rare case of CML developing a granulocytic sarcoma, that is an equivalent of a blast crisis, when the patient was in optimal response. I have never seen such a case in more than 40 years.

The pathologic material of the granulocytic sarcoma should be still available, to investigate if the sarcoma cells were Ph+ BCR-ABL+, and in that case if there was a BCR-ABL mutations.

If the pathologic material was analysed or can be analysed, and was Ph neg, BCR-ABL neg, I would suggest to continue the TKI, and to monitor very closely.

If the pathologic material was analysed or can be analysed, and was Ph+ BCR-ABL+, I would suggest to go to transplant. The risk of developing resistance would be very high.

If the pathologic material was not analysed and cannot be analysed, I would suggest to go to transplant as well, because morphology would not prove but would suggest that the granulocytic sarcoma was also Ph+ and BCR-ABL+.

Please, let me know the development.
  • Jeff Lipton
  • Jeff Lipton's Avatar
9 years 11 months ago #796 by Jeff Lipton
Replied by Jeff Lipton on topic Re: granulocytic sarcoma in a patient in MMR
A progression to granulocytic sarcoma on therapy is part of the definition of blast phase. There is a very high likelihood that the radiation alone did not deal with the problem and although the switch to dasatinib may help with temporarily with disease control, she will very likely progress again. I would suggest allografting as soon as possible, before she again loses repsonse and therapy necessary to get her into a transplantable state becomes more intense.
  • Kimmo Porkka
  • Kimmo Porkka's Avatar
9 years 11 months ago #797 by Kimmo Porkka
Replied by Kimmo Porkka on topic Re: granulocytic sarcoma in a patient in MMR
I agree with Dr. Baccarani, it would be very important to get a cytogenetic/molecular verification of a Ph+/BCR-ABL1+ sarcoma.

Almost 10 years ago we had a somewhat similar case on high-dose imatinib 800 mg/d with multiple spontaneous fractures in the hip and a histological diagnosis of a granulosarcoma. Due to the necrotic nature of the lesions, no proper cytogenetic or molecular verification could be done. The patient was treated with dasatinib (was not eligible for alloHSCT) and extensive hip replacement surgery, slowly recovered and has been in CMR for many years now.

I would do exactly as Dr. Baccarani suggested; if you get a verification of a BCR-ABL1-positive tumor (or are unable to do the examination), alloHSCT. Otherwise 2nd gen TKI with very careful follow-up.

Kimmo Porkka
More
9 years 11 months ago #798 by gsaglio
I totally agree with Michele's and Jeff's opinions
Moderators: Nicolaarlene